Stem cell company Mesoblast’s chief financial officer Josh Muntner will leave on August 30, and will be replaced by Andrew Chaponnel on an interim basis.
New York-based Mr Muntner will work closely with the board and management to co-ordinate the finalisation of the 2021 financial statements, the company said without providing any reason for his departure.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
